NEURL2: A Potential Drug Target and Biomarker (G140825)

Target Name: NEURL2

NCBI ID: G140825

NEURL2

NEURL2: A Potential Drug Target and Biomarker

Neuralized-like protein 2 (ISOFORM 1) is a protein that has been identified as a potential drug target and biomarker. It is a member of the neuralized-like protein family, which is a family of cytoskeletal proteins that are involved in the regulation of cell shape and movement. The neuralized-like protein family has been identified in a variety of organisms, including mammals, and is characterized by the presence of a unique N-terminal region that is involved in the formation of the protein.

One of the unique features of NEURL2 is its ability to interact with various signaling molecules, including TGF-β, Wnt, andNotch. These interactions make NEURL2 a potentially interesting drug target, as the regulation of cell shape and movement is involved in a wide range of physiological processes, including development, growth, and repair.

In addition to its potential as a drug target, NEURL2 has also been identified as a potential biomarker. The cytoskeleton is a complex structure that is involved in the regulation of many cellular processes, including cell division, migration, and mechanical forces. The neuralized- like protein family plays a key role in the regulation of these processes, and the disruption of NEURL2 has been linked to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The ability of NEURL2 to interact with signaling molecules makes it a potentially interesting drug target. TGF-β, in particular, has been shown to play a role in the regulation of cell shape and movement, and is involved in a wide range of processes, including cell growth, differentiation, and repair. The neuralized-like protein family has been shown to be involved in the regulation of TGF-β signaling, and the disruption of NEURL2 has been linked to TGF-β-related diseases.

In addition to its potential as a drug target, NEURL2 has also been identified as a potential biomarker for a variety of diseases. The neuralized-like protein family has been shown to be involved in the regulation of many cellular processes, including cell division, migration , and mechanical forces. The disruption of NEURL2 has been linked to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

For example, NEURL2 has been shown to be involved in the regulation of cell division and growth. In cancer cells, the disruption of NEURL2 has been linked to the development of a more aggressive and migratory phenotype. Similarly, in neurodegenerative diseases, such as Alzheimer's and Parkinson's, the disruption of NEURL2 has been linked to the development of neurodegeneration and the loss of cognitive function.

In conclusion, NEURL2 is a protein that has the potential to be a drug target and biomarker. Its unique ability to interact with various signaling molecules, including TGF-β, and its involvement in the regulation of cellular processes that are involved in many diseases make it a promising target for further research. Further studies are needed to fully understand the role of NEURL2 in disease and to develop effective treatments.

Protein Name: Neuralized E3 Ubiquitin Protein Ligase 2

Functions: Plays an important role in the process of myofiber differentiation and maturation. Probable substrate-recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex, which mediates the ubiquitination of proteins. Probably contributes to catalysis through recognition and positioning of the substrate and the ubiquitin-conjugating enzyme. During myogenesis, controls the ubiquitination and degradation of the specific pool of CTNNB1/beta-catenin located at the sarcolemma (By similarity)

The "NEURL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEURL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets